Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$76.94 USD
+1.00 (1.32%)
Updated May 7, 2024 04:00 PM ET
After-Market: $76.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AXSM 76.94 +1.00(1.32%)
Will AXSM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Other News for AXSM
Buy Rating Affirmed on Axsome Therapeutics Due to Strong Auvelity Sales and Promising Alzheimer’s Treatment Pipeline
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (HIMS), Axsome Therapeutics (AXSM) and Rocket Pharmaceuticals (RCKT)
Axsome Therapeutics (AXSM) Gets a Buy from RBC Capital
Buy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic Positioning
Axsome Therapeutics price target raised by $4 at Baird, here's why